Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations
Article first published online: 22 MAR 2010
© 2010 British Small Animal Veterinary Association
Journal of Small Animal Practice
Volume 51, Issue 4, pages 204–209, April 2010
How to Cite
Arteaga, A., Dhand, N. K., McCann, T., Knottenbelt, C. M., Tebb, A. J., Evans, H., Eckersall, P. D. and Ramsey, I. K. (2010), Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations. Journal of Small Animal Practice, 51: 204–209. doi: 10.1111/j.1748-5827.2009.00863.x
- Issue published online: 22 MAR 2010
- Article first published online: 22 MAR 2010
- Accepted: 5 October 2009
Background: Acute phase proteins (APPS) include haptoglobin (Hp), C-reactive protein (CRP) and serum amyloid A (SAA). Increased Hp concentrations may be induced by endogenous or exogenous glucocorticoids in dogs.
Objectives: To assess whether control of hyperadrenocorticism (HAC) affects the concentrations of Hp, CRP, SAA, alkaline phosphatase (ALKP) and cholesterol, to determine whether these analytes can be used to assess control of HAC following trilostane treatment, and whether a combination of these tests offers a valid method of assessing disease control.
Methods: Hp, CRP, SAA, ALKP and cholesterol were assessed in 11 dogs with spontaneous HAC before and after treatment with trilostane. Adequate control of HAC was defined as post-ACTH cortisol less than 150 nmol/l.
Results: Significant reductions in Hp, ALKP, cholesterol and SAA (P<0·05) but not of CRP were found after control of HAC. Only Hp, cholesterol and ALKP were moderately informative (Se & Sp>0·7) of disease control when compared to adrenocorticotropin or corticotropin (ACTH) stimulation test. SAA and CRP were unhelpful (Se & Sp<0·7). The analysis of the combination of the analytes did not improve the correlation with ACTH stimulation test.
Clinical Relevance: Relying on these analytes does not provide additional information over ACTH stimulation test results when assessing control of HAC treated with trilostane.